Developer docs
API playgroundTry for free, no card

Search company profiles

SemperVirens Venture Capital

Full company profile

uuid0000org

Namestring
SemperVirens Venture Capital
Legal namestring
SemperVirens Ventures LLC
Company typeenum
Private
Founded yearint
2018
Descriptiontext

SemperVirens Venture Capital is an ecosystem-driven, early-stage venture capital firm that invests in AI-native startups across three thematic verticals: healthtech, worktech (workforce technology), and fintech. The firm is headquartered in San Mateo, California, operates as SemperVirens Ventures LLC, and reports more than $300 million raised cumulatively from institutional, strategic, and impact-oriented limited partners across two investment vehicles, including a $177 million healthcare and workforce technology fund closed in March 2025 with Sequoia and DPI reported among its LPs.

The firm's offering is structured as a platform-plus-modules architecture rather than a single fund product. Its core capital product is selective, stage-specific investment from accelerator through growth funds, with a published portfolio that includes six unicorns spanning Midi Health, Stepful, Spring Health, Rula, Multiverse, Rightway, Ashby, and Human Interest. On top of this, it operates the SemperVirens Accelerator — a curated cohort-of-four program for early-stage B2B startups that includes a built-in investment component — and the SemperVirens Ecosystem, a proprietary value-creation platform spanning Access (warm introductions to 8,000+ enterprise buyers and channel partners), Insights (portfolio benchmarking and buyer feedback), Amplification (go-to-market program design), and an Advisor Network of 200+ executive advisors including former CHROs, CPOs, and healthcare executives from companies such as IBM, ADP, Disney, Hilton, Visa, McKesson, and Walmart.

SemperVirens monetizes through standard venture-fund economics: recurring management fees on committed and invested capital, performance-based carried interest on fund returns, and capital returns on accelerator-stage investments. The firm does not publicly disclose management fee rates, fund minimums, or carry terms. Its go-to-market with portfolio companies emphasizes distribution-led value creation, with reported metrics of 5,000+ customer introductions and 1,000+ deals driven through partner distribution channels across the portfolio, and a stated $175M+ in directly influenced ARR. The team consists of approximately 14 named professionals led by two Managing Partners and two General Partners, supported by 200+ external executive advisors. The 2025 Year in Review reports top decile and top quartile performance across flagship funds and the return of over half of Fund I.

Short descriptiontext

SemperVirens Venture Capital is an ecosystem-driven early-stage venture firm investing in AI-native startups across healthtech, worktech, and fintech, deploying $300M+ across two fund vehicles, operating a cohort-based accelerator, and running a proprietary distribution platform connecting portfolio companies to 8,000+ enterprise buyers and 200+ executive advisors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, early-stage startups, healthtech venture capital, worktech venture capital, fintech venture capital
Industry1 code
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
Product category
Venture Capital
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1Fund Management Fees
TypeSubscription Recurring
Description

Recurring management fees on $300M+ raised from institutional, strategic, and impact-oriented LPs. Two distinct investment vehicles support companies by stage, from accelerator to growth funds.

sempervirensvc.com
2Carried Interest & Fund Returns
TypeManaged Services
Description

Performance-based returns from $177M healthcare and workforce tech fund (Fortune coverage, March 2025) with LPs including Sequoia. 2025 Year in Review noted returning over half of Fund I with top decile/quartile performance across flagship funds.

sempervirensvc.com
3Accelerator Program Investment Returns
TypeProfessional Services
Description

Built-in investment component within the Accelerator program (curated cohort of four) supports participating companies and deepens long-term alignment, generating capital returns on accelerator-stage investments.

sempervirensvc.com
Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1SemperVirens Accelerator
Description

The firm's venture capital accelerator program, helping early-stage B2B startups sharpen their distribution strategy, connect with industry leaders, and scale faster. Includes a built-in investment component.

sempervirensvc.com
Core offering1 text field

SemperVirens Venture Capital is an early-stage ecosystem venture capital firm that raises capital from institutional, strategic, and impact-oriented limited partners and invests it in AI-native startups across healthtech, worktech, and fintech. The firm supplements its fund vehicles with a curated Accelerator program (cohorts of four) and a proprietary Ecosystem platform providing enterprise introductions, advisory support, and channel partnerships to accelerate portfolio company go-to-market.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

SemperVirens Venture Capital is an ecosystem-driven venture capital firm delivering a platform-plus-modules architecture rather than a single product. Its core offering is selective, stage-specific capital deployed through its Venture Capital Fund(s), supplemented by the SemperVirens Accelerator program for early-stage B2B startups and the SemperVirens Ecosystem (an integrated value-creation platform spanning Access, Insights, Amplification, and an Advisor Network of 200+ executive advisors). Together, the Fund(s) provide investment capital, the Accelerator delivers hands-on distribution and GTM support with a built-in investment component, and the Ecosystem unlocks warm introductions, buyer feedback, and channel partnerships to accelerate portfolio companies across healthtech, worktech, and fintech.

Product and service3 records
1SemperVirens Venture Capital Fund(s)
CategoryVenture Capital Fund
Description

Selective, stage-specific venture capital investment vehicles providing capital from accelerator stage through growth funds. The firm has raised $300M+ from institutional, strategic, and impact-oriented LPs and reports $175M+ in directly influenced ARR across the portfolio. Portfolio spans healthtech, worktech, and fintech categories.

2SemperVirens Accelerator
CategoryVenture Accelerator Program
Description

VC accelerator program for early-stage B2B startups operating in small curated cohorts of four. Provides 1:1 strategic advisory, distribution-focused programming, executive events, access to a GTM network, and a built-in investment component. Supports companies at pre-revenue through early-pilot stages.

3SemperVirens Ecosystem
CategoryPortfolio Support Platform
Description

Proprietary value-creation platform comprising four modules: Access (warm introductions to 8,000+ enterprise buyers and channel partners), Insights (benchmarks and buyer feedback), Amplification (go-to-market program design and channel partnerships), and an Advisor Network (200+ executive advisors across an Executive Advisory Board, Healthcare Advisory Board, and HR Venture Advisors).

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Early-stage venture firm led by Aileen Lee (named in SemperVirens' ecosystem). Operates a similar stage-specific, thesis-driven model and is explicitly cited as a SemperVirens ecosystem partner.

TypeBroad incumbent
Description

Large multi-stage venture firm with a deep healthtech franchise (analogous to SemperVirens' healthtech pillar) and a platform/value-creation model. Overlaps directly in healthcare AI, benefits, and workforce categories.

TypeBroad incumbent
Description

Largest U.S. venture platform with explicit Bio/Health and Work theses and a well-known platform playbook (enterprise buyer introductions, executive networks) that mirrors SemperVirens' Ecosystem strategy at much greater scale.

TypeBroad incumbent
Description

Long-standing venture firm with strong healthtech and AI portfolios and willingness to back bold, contrategory theses. Directly comparable in appetite for AI-native category-defining bets in complex markets.

TypeBroad incumbent
Description

Multi-stage firm with strong healthcare and SaaS/cloud franchises and a published "anti-portfolio" track record. Comparable on stage range, healthcare exposure, and platform support for portfolio GTM.

TypeDirect peer
TypeBroad incumbent
Description

Multi-stage firm with active healthtech, worktech, and consumer fintech investments. Comparable in stage range and AI-native appetite, and competes with SemperVirens on later-stage pro-rata rounds.

TypeBroad incumbent
Description

Peter Thiel-led multi-stage venture firm with significant healthtech and AI exposure. Comparable in willingness to back contrarian, category-defining AI bets in regulated and complex markets.

TypeBroad incumbent
Description

Multi-stage corporate-affiliated venture firm with deep healthtech and AI expertise. Direct overlap with SemperVirens' healthcare and AI-native worktech investments (e.g., co-investor in Midi Health).

TypeDirect peer
Description

Healthcare-focused venture firm that led 9amHealth's $26M Series B in which SemperVirens participated. Closest pure-play healthtech peer with similar stage and AI-driven thesis.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment105 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SemperVirens Venture Capital

Venture Capitalsempervirensvc.com

SemperVirens Venture Capital is an ecosystem-driven early-stage venture firm investing in AI-native startups across healthtech, worktech, and fintech, deploying $300M+ across two fund vehicles, operating a cohort-based accelerator, and running a proprietary distribution platform connecting portfolio companies to 8,000+ enterprise buyers and 200+ executive advisors.

What SemperVirens Venture Capital does

SemperVirens Venture Capital is an ecosystem-driven, early-stage venture capital firm that invests in AI-native startups across three thematic verticals: healthtech, worktech (workforce technology), and fintech. The firm is headquartered in San Mateo, California, operates as SemperVirens Ventures LLC, and reports more than $300 million raised cumulatively from institutional, strategic, and impact-oriented limited partners across two investment vehicles, including a $177 million healthcare and workforce technology fund closed in March 2025 with Sequoia and DPI reported among its LPs.

The firm's offering is structured as a platform-plus-modules architecture rather than a single fund product. Its core capital product is selective, stage-specific investment from accelerator through growth funds, with a published portfolio that includes six unicorns spanning Midi Health, Stepful, Spring Health, Rula, Multiverse, Rightway, Ashby, and Human Interest. On top of this, it operates the SemperVirens Accelerator — a curated cohort-of-four program for early-stage B2B startups that includes a built-in investment component — and the SemperVirens Ecosystem, a proprietary value-creation platform spanning Access (warm introductions to 8,000+ enterprise buyers and channel partners), Insights (portfolio benchmarking and buyer feedback), Amplification (go-to-market program design), and an Advisor Network of 200+ executive advisors including former CHROs, CPOs, and healthcare executives from companies such as IBM, ADP, Disney, Hilton, Visa, McKesson, and Walmart.

SemperVirens monetizes through standard venture-fund economics: recurring management fees on committed and invested capital, performance-based carried interest on fund returns, and capital returns on accelerator-stage investments. The firm does not publicly disclose management fee rates, fund minimums, or carry terms. Its go-to-market with portfolio companies emphasizes distribution-led value creation, with reported metrics of 5,000+ customer introductions and 1,000+ deals driven through partner distribution channels across the portfolio, and a stated $175M+ in directly influenced ARR. The team consists of approximately 14 named professionals led by two Managing Partners and two General Partners, supported by 200+ external executive advisors. The 2025 Year in Review reports top decile and top quartile performance across flagship funds and the return of over half of Fund I.

SemperVirens Venture Capital firmographics

Firmographics
Name
SemperVirens Venture Capital
Legal name
SemperVirens Ventures LLC
Website
https://sempervirensvc.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Short description
SemperVirens Venture Capital is an ecosystem-driven early-stage venture firm investing in AI-native startups across healthtech, worktech, and fintech, deploying $300M+ across two fund vehicles, operating a cohort-based accelerator, and running a proprietary distribution platform connecting portfolio companies to 8,000+ enterprise buyers and 200+ executive advisors.
Ownership category
akta.pro rank

SemperVirens Venture Capital industry classification

Industry
Product category
Venture Capital
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)

Keywords

  • Venture capital investing
  • Early-stage startups
  • Healthtech venture capital
  • Worktech venture capital
  • Fintech venture capital

Where SemperVirens Venture Capital is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

SemperVirens Venture Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Fund Management Fees: Recurring management fees on $300M+ raised from institutional, strategic, and impact-oriented LPs. Two distinct investment vehicles support companies by stage, from accelerator to growth funds.
  2. Carried Interest & Fund Returns: Performance-based returns from $177M healthcare and workforce tech fund (Fortune coverage, March 2025) with LPs including Sequoia. 2025 Year in Review noted returning over half of Fund I with top decile/quartile performance across flagship funds.
  3. Accelerator Program Investment Returns: Built-in investment component within the Accelerator program (curated cohort of four) supports participating companies and deepens long-term alignment, generating capital returns on accelerator-stage investments.

Go-to-market motion4 records

SemperVirens Venture Capital product offering

Product offering

Core offering

SemperVirens Venture Capital is an early-stage ecosystem venture capital firm that raises capital from institutional, strategic, and impact-oriented limited partners and invests it in AI-native startups across healthtech, worktech, and fintech. The firm supplements its fund vehicles with a curated Accelerator program (cohorts of four) and a proprietary Ecosystem platform providing enterprise introductions, advisory support, and channel partnerships to accelerate portfolio company go-to-market.

Product overview

SemperVirens Venture Capital is an ecosystem-driven venture capital firm delivering a platform-plus-modules architecture rather than a single product. Its core offering is selective, stage-specific capital deployed through its Venture Capital Fund(s), supplemented by the SemperVirens Accelerator program for early-stage B2B startups and the SemperVirens Ecosystem (an integrated value-creation platform spanning Access, Insights, Amplification, and an Advisor Network of 200+ executive advisors). Together, the Fund(s) provide investment capital, the Accelerator delivers hands-on distribution and GTM support with a built-in investment component, and the Ecosystem unlocks warm introductions, buyer feedback, and channel partnerships to accelerate portfolio companies across healthtech, worktech, and fintech.

Differentiator

Problem solved

Functional benefit

Brands

  • SemperVirens Accelerator: The firm's venture capital accelerator program, helping early-stage B2B startups sharpen their distribution strategy, connect with industry leaders, and scale faster. Includes a built-in investment component.

Products and services

  • SemperVirens Venture Capital Fund(s) Selective, stage-specific venture capital investment vehicles providing capital from accelerator stage through growth funds. The firm has raised $300M+ from institutional, strategic, and impact-oriented LPs and reports $175M+ in directly influenced ARR across the portfolio. Portfolio spans healthtech, worktech, and fintech categories.
  • SemperVirens Accelerator VC accelerator program for early-stage B2B startups operating in small curated cohorts of four. Provides 1:1 strategic advisory, distribution-focused programming, executive events, access to a GTM network, and a built-in investment component. Supports companies at pre-revenue through early-pilot stages.
  • SemperVirens Ecosystem Proprietary value-creation platform comprising four modules: Access (warm introductions to 8,000+ enterprise buyers and channel partners), Insights (benchmarks and buyer feedback), Amplification (go-to-market program design and channel partnerships), and an Advisor Network (200+ executive advisors across an Executive Advisory Board, Healthcare Advisory Board, and HR Venture Advisors).

Companies that use SemperVirens Venture Capital

Customer profile

Named customers14 records

Segments5 records

Ideal customer profiles3 records

SemperVirens Venture Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

SemperVirens Venture Capital partnerships and signals

Strategic signal

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

SemperVirens Venture Capital competitors and assessment

Company assessment

Direct peers

  • Cowboy Ventures: Early-stage venture firm led by Aileen Lee (named in SemperVirens' ecosystem). Operates a similar stage-specific, thesis-driven model and is explicitly cited as a SemperVirens ecosystem partner.
  • Forerunner Ventures:
  • Define Ventures: Healthcare-focused venture firm that led 9amHealth's $26M Series B in which SemperVirens participated. Closest pure-play healthtech peer with similar stage and AI-driven thesis.

Broad incumbents

  • General Catalyst: Large multi-stage venture firm with a deep healthtech franchise (analogous to SemperVirens' healthtech pillar) and a platform/value-creation model. Overlaps directly in healthcare AI, benefits, and workforce categories.
  • Andreessen Horowitz (a16z): Largest U.S. venture platform with explicit Bio/Health and Work theses and a well-known platform playbook (enterprise buyer introductions, executive networks) that mirrors SemperVirens' Ecosystem strategy at much greater scale.
  • Khosla Ventures: Long-standing venture firm with strong healthtech and AI portfolios and willingness to back bold, contrategory theses. Directly comparable in appetite for AI-native category-defining bets in complex markets.
  • Bessemer Venture Partners: Multi-stage firm with strong healthcare and SaaS/cloud franchises and a published "anti-portfolio" track record. Comparable on stage range, healthcare exposure, and platform support for portfolio GTM.
  • Lightspeed Venture Partners: Multi-stage firm with active healthtech, worktech, and consumer fintech investments. Comparable in stage range and AI-native appetite, and competes with SemperVirens on later-stage pro-rata rounds.
  • Founders Fund: Peter Thiel-led multi-stage venture firm with significant healthtech and AI exposure. Comparable in willingness to back contrarian, category-defining AI bets in regulated and complex markets.
  • GV (Google Ventures): Multi-stage corporate-affiliated venture firm with deep healthtech and AI expertise. Direct overlap with SemperVirens' healthcare and AI-native worktech investments (e.g., co-investor in Midi Health).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

SemperVirens Venture Capital social profiles

Digital presence

SemperVirens Venture Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SemperVirens Venture Capital leadership team

Management profile

Number of profiles

Profiles14 records

SemperVirens Venture Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SemperVirens Venture Capital M&A and investment

M&A and investment

M&A

Investments105 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SemperVirens Venture Capital

What does SemperVirens Venture Capital do?

SemperVirens Venture Capital is an early-stage ecosystem venture capital firm that raises capital from institutional, strategic, and impact-oriented limited partners and invests it in AI-native startups across healthtech, worktech, and fintech. The firm supplements its fund vehicles with a curated Accelerator program (cohorts of four) and a proprietary Ecosystem platform providing enterprise introductions, advisory support, and channel partnerships to accelerate portfolio company go-to-market.

Is SemperVirens Venture Capital a public or private company?

SemperVirens Venture Capital is a private company. It is classified as venture growth investor backed and is currently operating.

When was SemperVirens Venture Capital founded?

SemperVirens Venture Capital was founded in 2018. It employs 101 to 250 people.

Where is SemperVirens Venture Capital based?

SemperVirens Venture Capital is headquartered in San Francisco, United States, in the North America region.

How does SemperVirens Venture Capital make money?

Three revenue lines are on record. Fund Management Fees are the primary driver. The others are carried Interest & Fund Returns and accelerator Program Investment Returns.

Who are SemperVirens Venture Capital's main competitors?

Direct peers on record are Cowboy Ventures, Forerunner Ventures and Define Ventures. Broad incumbents are General Catalyst, Andreessen Horowitz (a16z), Khosla Ventures, Bessemer Venture Partners, Lightspeed Venture Partners, Founders Fund and GV (Google Ventures).

Does SemperVirens Venture Capital have an API?

No public API is recorded for SemperVirens Venture Capital.

What industry is SemperVirens Venture Capital in?

SemperVirens Venture Capital's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WebrazziSağlık sigortası platformu Thatch, 1 milyar dolar değerleme ile 108 milyon dolar yatırım aldıThatch, a US-based health insurance platform, raised $108 million at a $1 billion valuation. The round included The General Partnership, Index Ventures, General Catalyst, and Andreessen Horowitz. The company's revenue grew about sevenfold in the past year, and it serves over 5,000 employers.Venture Capital Access OnlineThatch Raises $108M at $1B Valuation as Employers Shift Away From Traditional Health PlansThatch raised $108 million at a $1 billion valuation from The General Partnership, Index Ventures, General Catalyst, and Andreessen Horowitz. The health benefits platform, used by over 5,000 employers, has grown revenue nearly seven-fold in the past year. The company aims to shift employers from traditional group plans to individual health budgets.Business Wire BlogEpsilon Health Raises $27.6 Million to Solve America’s Growing Radiologist ShortageEpsilon Health emerged from stealth with $27.6 million in funding led by AlleyCorp. The AI-native radiology practice has served over 250,000 patients and processes more than 2,500 imaging studies daily, on track to review 1% of all daily U.S. X-rays in 2026.Venture Capital Access OnlineEpsilon Health Raises $27.6 Million to Solve America’s Growing Radiologist ShortageEpsilon Health emerged from stealth with $27.6 million in funding led by AlleyCorp. The AI-native radiology practice has served over 250,000 patients and processes more than 2,500 imaging studies daily, on track to review 1% of all daily U.S. X-rays in 2026.36kr$55M in Series C Financing Secured: 3.2M Talent Gaps Drive Boom of US Medical Vocational TrainingStepful, a US medical vocational training platform, completed a $55 million Series C financing round led by Oak HC/FT. The company trains medical assistants, pharmacy technicians, and surgical technicians, with over 32,000 professionals placed and 35+ medical networks using its platform. Funds will expand into higher-level certifications like registered nurses and respiratory therapy.Venture Capital Access OnlineStepful Announces $55M Series C to Scale Its AI-Powered Training Platform Across the Healthcare WorkforceStepful announced $55 million in Series C funding led by Oak HC/FT, with participation from Foresite Capital, Hearst Ventures, and the Citi Impact Fund. The company has graduated over 32,000 practice-ready healthcare workers since its founding. The capital will expand partnerships and launch advanced degree programs in nursing, respiratory therapy, and imaging.Business Wire BlogStepful Announces $55M Series C to Scale Its AI-Powered Training Platform Across the Healthcare WorkforceStepful announced $55 million in Series C funding led by Oak HC/FT, with participation from Foresite Capital, Hearst Ventures, and the Citi Impact Fund. The company has graduated over 32,000 practice-ready healthcare workers since its founding. The capital will expand partnerships and launch advanced degree programs in nursing, respiratory therapy, and imaging.VC News DailyKubera Health Raises $6.5M Seed RoundKubera Health raised $6.5 million in seed funding led by Upfront Ventures, with participation from Company Ventures, Dria Ventures, and SemperVirens. The company is building a contract-to-payment system for American healthcare that translates payor-provider agreements into structured rules for claims and payment data.FinSMEsKubera Health Raises $6.5M in Seed FundingKubera Health, a NYC-based healthcare contract-to-payment system developer, raised $6.5M in seed funding led by Upfront Ventures. The company will use the funds to invest in product, engineering, and go-to-market teams as it expands across value-based care and other contract structures.Vestbee9amHealth raises $26M to expand AI-driven chronic care platform beyond cardiometabolic health9amHealth raised $26 million in Series B funding led by Define Ventures to expand its AI-driven virtual specialty care platform beyond cardiometabolic conditions. The California-based firm will use the funds to scale clinical operations and technology for additional high-cost chronic conditions, aiming to reduce employer healthcare costs.